Decentralized Clinical Trial (DCT) Platform

A decentralized clinical trial (DCT) platform is the connected software and service layer — telehealth, eConsent, direct-to-patient investigational product (IMP) shipment, local/mobile data collection, and eCOA/device integrations — that lets some or all trial visits and procedures happen outside a traditional investigative site. FDA does not treat “decentralized” as a separate regulatory pathway or trial category; a DCT is conducted under the same IND/IDE, Good Clinical Practice (GCP), informed-consent, and safety-reporting requirements as any other trial. What changes is where and how specific activities are performed, and a DCT platform is the operational infrastructure that makes distributing those activities auditable and consistent across participants.

FDA’s recognition of decentralized elements

FDA finalized guidance for industry, investigators, and other stakeholders titled Conducting Clinical Trials With Decentralized Elements, announced via Federal Register notice on September 18, 2024, following an earlier 2023 draft. The guidance applies across drugs, biological products, and devices and addresses how sponsors should apply existing IND/IDE, GCP, and informed-consent requirements when trial activities — visits, assessments, specimen collection, drug administration — occur at a participant’s home, a local clinic, or via telehealth rather than solely at the investigative site named in the protocol. It does not create a new trial category; a trial with decentralized elements is still governed by the same regulatory framework (see ICH E6(R3) and the Common Rule) as a fully site-based one.

What a DCT platform typically bundles

• Telehealth/remote visit tooling — video or audio encounters with the investigator or a delegated sub-investigator in place of, or alongside, in-person site visits.
• Remote informed consent (eConsent) — electronic presentation and capture of consent for participants enrolling or continuing to participate without traveling to the site; see eConsent.
• Home health or mobile nursing services — a contracted local clinician performs a scheduled procedure (vitals, injections, specimen draw) in the participant’s home under delegated authority from the investigator.
• Local labs and pharmacies — routine labwork or investigational product dispensing performed at a facility near the participant instead of the central site, requiring the platform to route results/dispensing records back to the trial’s central systems.
• Direct-to-patient (DtP) IMP shipment — investigational product shipped from a depot or central pharmacy directly to the participant, with temperature and chain-of-custody tracking; this interacts closely with clinical trial supply management.
• eCOA/ePRO and connected devices — participant-reported outcomes and, increasingly, wearable or sensor data captured between visits; see ePRO and wearable devices and digital health technologies (DHTs).
• Central data integration — the above feed into the trial’s electronic data capture (EDC) system and safety database, ideally without manual re-entry, so remote-collected data carries the same audit trail as site-collected data.

Not every DCT uses every component above. Most real-world trials are hybrid: certain visits or procedures (e.g., imaging, a specific procedural exam) still require the physical site, while others (routine vitals, medication counseling, PRO capture) are decentralized. A DCT platform’s job is to make that mixed model manageable from a single operational and data-oversight view rather than as disconnected point tools.

Administrative and regulatory considerations

Decentralizing where a trial activity happens does not decentralize who is accountable for it. Several administrative burdens are specific to DCT platforms and don’t arise in a purely site-based trial:

• Multi-state (or multi-jurisdiction) licensure. A telehealth investigator, a home-health nurse, or a local lab performing a delegated trial procedure must generally be licensed to practice in the jurisdiction where the participant is physically located at the time of the encounter, not only where the investigator or site is based. This becomes a real operational constraint at national or multi-region enrollment scale, and sponsors and CROs typically maintain jurisdiction-by-jurisdiction licensure and credentialing checks as part of site activation for a DCT.
• IRB oversight of remote and delegated activities. The trial’s IRB of record remains responsible for reviewing and approving the protocol’s decentralized elements — including consent conducted remotely, home-visit procedures, and use of local facilities as data-collection points — not just the central site’s procedures. See IRB (Institutional Review Board).
• Delegation of authority beyond the site. Every individual performing a delegated trial procedure — a local phlebotomist, a home-health nurse, a community pharmacist — needs to be documented on the delegation-of-authority log with training records, the same as site staff, and needs a clear line of monitoring oversight from the sponsor or CRO.
• Data provenance and audit trail. Because data now originates from multiple, geographically distributed sources (local labs, home-health visits, participant devices) rather than a single site’s records, the platform’s integration layer has to preserve source-data traceability and timestamps consistently with 21 CFR Part 11 expectations across all of those sources, not just the central EDC.
• Participant safety monitoring at a distance. Adverse-event detection and reporting timelines don’t change because a visit was remote; sponsors need a defined escalation path from a home-health visit or telehealth encounter into the trial’s standard safety-reporting workflow.

None of this is unique to any particular vendor’s product — it applies to the DCT operating model generally, whichever platform or combination of point solutions a sponsor selects. Procurement and evaluation should focus on how well a given platform’s components integrate with each other and with the trial’s EDC/safety systems, and how clearly it supports jurisdiction-aware credentialing and delegation tracking, rather than on any single feature in isolation.

Related concepts

• Decentralized Clinical Trials (DCTs): What They Are, FDA Guidance, and Key Components — the fuller guide-length treatment of the DCT model this term sits under.
• Clinical Trial Management System (CTMS)
• Electronic Trial Master File (eTMF)
• Informed consent in research